资源描述
,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,老年晚期肺癌患者的药物选择,主要内容,背景,细胞毒药物化疗,分子靶向治疗,总结,4,1,2,3,主要内容,背景,1,主要内容,细胞毒药物化疗,2,细胞毒药物化疗,单药化疗,长春瑞滨,长春瑞滨单药方案可延长老年,NSCLC,患者中位生存期(,MST,),提高,1,年生存率,但与含铂类两药联合化疗方案相比,没有延长总生存时间。,6Devlin JG,et al.Clin Lung Cancer,2007,8(5):319-326.,细胞毒药物化疗,单药化疗,紫杉醇,方法:,27,名,NSCLC,患者(,B/,期),平均年龄,73,岁(,70-83,岁),其中,16,名患者有并发症。给予紫杉醇(,80mg/m,2,,第,1,、,8,、,15,天,每,4,周,1,次)方案治疗。,结果:,平均进展时间为,5,个月,平均生存时间,12,个月;,7,例出现乏力,,1,例出现过敏反应,无其他的,3/4,级毒性反应。,结论:,紫杉醇每周方案(,80mg/m,2,)疗效确切且安全性高,在老年患者可作为替代长春瑞滨或吉西他滨的一线治疗方案,尤其是存在并发症的患者。,7Rossi D,et al.Clin Lung Cancer,2008,9(5):280-284.,细胞毒药物化疗,单药化疗,吉西他滨,方法:,47,例,NSCLC,患者,(B-,期,),,平均年龄,73,岁,(70-82,岁,),,,第,1,、,8,、,15,天应用吉西他滨,(1000mg/m,2,),,每,28,天为,1,个周期。,结果:,总有效率为,21.7%,,中位生存期,8.4,个月。,度白细胞减少为,19.0%,,非血液学毒性少见,无,度骨髓抑制。,结论:吉西他滨单药用于老年,NSCLC,患者疗效较好,毒性较低。,8Martoni A,et al.Am J Clin Oncol,2001,24(6):614-617.,细胞毒药物化疗,非铂类联合化疗,RCT,试验,方法:,707,例老年,B,、,期,NSCLC,患者随机分为,3,组,分别给予:,A,组:长春瑞滨(,NVB,,,30mg/m,2,);,B,组:吉西他滨(,GEM,,,1200mg/m,2,);,C,组:长春瑞滨(,NVB,,,25mg/m,2,),+,吉西他滨(,GEM,,,1000mg/m,2,),,所有药物均为第,1,、,8,天给药,,3,周为,1,周期最多,6,个周期。,9Gridelli C,et al.J Natl Cancer Inst,2003,95(5):362-372.,细胞毒药物化疗,非铂类联合化疗,RCT,试验,结果,2,C,组与,A,组比较,血小板减少、肝毒性发生率显著升高(,P,0.05,);,C,组与,B,组比较,中性粒细胞减少、呕吐、乏力、心脏毒性、便秘等发生率显著升高(,P,0.05,)。,9Gridelli C,et al.J Natl Cancer Inst,2003,95(5):362-372.,方法:,451,例,70-80,岁晚期,NSCLC,患者随机分为,3,组,分别给予:,A,组:长春瑞滨;,B,组:吉西他滨;,C,组:紫杉醇,+,卡铂,结果显示:结果显示,采用两药化疗患者的中位生存时间(,10.3,个月)长于单药化疗(,6.2,个月,,0.01,);两药化疗患者更易发生骨髓抑制和肌无力,但均可耐受,细胞毒药物化疗,铂类联合化疗,1.,NCCN,指南,以铂类为基础的联合化疗是晚期成年,NSCLC,患者的一线标准治疗方案,疗效优于单药化疗。,2.,铂类副作用,明显的胃肠道、肾脏、神经系统毒性,老年人是否耐受较有争议。,3.,铂类的选择,研究表明,10,,卡铂和顺铂在晚期,NSCLC,一线治疗中对总生存无显著差异。,4.,铂类联合化疗用于老年,NSCLC,患者的临床试验,11,适当降低用药量或采用每周给药方案,结果卡铂联合方案疗效及患者耐受性均较好,因此,推荐一般情况好的老年患者可采用低剂量卡铂、顺铂联合方案化疗,但在用药期间应密切关注可能发生的血液毒性及消化道毒性反应,并及时采取相应的防治措施。,10,蒋京伟,等,.,中华医学杂志,,2006,,,86,(,37,):,2615-2620.,11Hiroshi Takatani,et al.Clin Lung Cancer,2012 Jan 18.,主要内容,分子靶向治疗,3,分子靶向治疗,厄洛替尼:,EURTAC,研究,12Resell R,,,et a1,Lancet Once1,,,2012,,,3(3),:,239-246.,分子靶向治疗,EURTAC,研究:,RCT,试验,方法:,173,例,EGFR,敏感突变的晚期,NSCLC,患者,(B-,期,),,,65,岁患者,88,例,,65,岁,85,例。随机分为厄洛替尼组和含铂两药(吉西他滨或多西他赛)化疗组,主要终点事件为,PFS,。,结果:,1.,厄洛替尼组中位,PFS,为,9.7,个月,化疗组仅,5.2,个月(,P,0.001,);,2.3-4,度不良反应主要为皮疹(厄洛替尼组,13%,,化疗组,0,)和中性粒细胞减少(厄洛替尼组,0,,化疗组,22%,)。,3.,165,岁患者同样获益,(HR=0.28,,,P=0.496),。,基于,EURTAC,研究:,2013,年,5,月美国,FDA,批准厄洛替尼一线治疗,EGFR,敏感突变的晚期,NSCLC,患者,13,。,13Khozin S,,,et a1,Oncologist,,,2014,,,19(7),:,774-779,分子靶向治疗,贝伐单抗,研究类型,研究内容,结论,前瞻性研究,AVAIL,研究,17,:,RCT,试验,GCB,方案可,明显提高,患者的,PFS,,且不良反应可耐受。,回顾性研究,Leighl,等,18,:,回顾性分析,AVAIL,研究中,304,例老年,(65,岁,),晚期肺癌患者应用,GCB,方案的疗效和安全性。,GCB,方案可以延长老年肺癌患者的生存时间且耐受性,良好,。,GCB,方案:贝伐单抗,+,吉西他滨,+,顺铂,17 Reek M,,,et a1,Ann Oncol,,,2010,,,(9),:,18041809.,18Leighl NB,,,et a1,J Thorac Oncol,,,2010,,,5(12),:,19701976,分子靶向治疗,贝伐单抗,研究类型,研究内容,结论,前瞻性研究,SAiL,研究,19,:,RCT,试验,老年晚期非鳞,NSCLC,患者一线应用贝伐单抗联合标,准化疗方案同样,安全有效,。,前瞻性研究,ARIES,研究,20,:,RCT,试验,贝伐单抗联合标准化疗方案,19I Crinb L,,,et a1,Lancet 0ncel,,,2010,,,1(8),:,733,740,20LynehTJ Jr,,,et a1,J Thorac 0ncol,,,2014,,,9(9),:,13321339,总结,1.,老年肺癌患者的药物治疗需要权衡患者的一般情况评分、考察肝肾功能和患者意愿等,实施个体化治疗,以便为患者更合理的选择化疗药物。,2.,可应用长春瑞滨等单药化疗、含铂两药化疗(,PS,评分好)、针对,EGFR,敏感突变的小分子靶向药物厄洛替尼、含贝伐单抗的联合治疗(非鳞癌)等。,3.,用药过程中需密切观察患者的毒副反应,并及时采取相应的防治措施。,参考文献,1Torre LA,,,Bray F,,,Siegel RL,,,et a1,Global cancer statistics,,,2012,J,CA Cancer J Clin,,,2015,,,65(2),:,87108,2Siegel R,,,Ma J,,,Zou Z,,,et a1,Cancer statistics,,,2014J,CA Cancer J Clin,,,2014,,,64(1),:,929,3Owonikoko TK,,,Ragin CC,,,Belani CP,,,et a1,Lung cancelin elderly patients,:,an analysis of the surveillance,,,epidemiology,,,an d end results databaseJ,J Clin Oncol,,,2007,,,25(35),:,55705577,4Chen W,,,Zheng R,,,S,,,et a1,Report ofincidence and mortality,in China cancer registries,,,2OO9J,Chin J Cancer Res,,,2013,,,25,(1),:,1O,一,21,5SacherAG,,,Le LW,,,LeighlNB,,,eta1,Eldedy patientswith advanced NSCLC in phase In clinical trials,:,are the elderly eXClUded from practicechanging trials in advanced NSCLC?J,J Thorae Oncol,,,2013,,,8(3),:,366368,6Devlin JG,Langer CJ.Salvage therapy with vinorelbine in advanced non-small-cell lung cancer:a retrospective review of,the Fox Chase Cancer Center experience and a review of the literatureJ.Clin Lung Cancer,2007,8(5):319-326.,Devlin JG,et al.Clin Lung Cancer,2007,8(5):319-326.,7Rossi D,Dennetta D,Ugolini M,et al.Weekly paclitaxel in elderly patients(aged or=70 years)with advanced non-small-cell lung cancer:an alternative choice?Results of a phase II studyJ.Clin Lung Cancer,2008,9(5):280-284.,Rossi D,et al.Clin Lung Cancer,2008,9(5):280-284.,8Martoni A,Di Fabio F,Guaraldi M,et al.Prospective phase,study of single agent gemcitabine in untreated elderly patients with stage B/non-small-cell lung cancerJ.Am J Clin Oncol,2001,24(6):614-617.,Martoni A,et al.Am J Clin Oncol,2001,24(6):614-617.,9Gridelli C,Perrone F,Gallo C,et al.Chemotherapy for elderly patients with advanced non-small-cell lung cancer:the multicenter Italian lung cancer in the elderly study (MILES)phase randomized trialJ.J Natl Cancer Inst,2003,95(5):362-372.,Gridelli C,et al.J Natl Cancer Inst,2003,95(5):362-372.,10,蒋京伟,梁晓华,周鑫莉,等,.,卡铂与顺铂治疗晚期非小细胞肺癌疗效的荟萃分析,J.,中华医学杂志,,2006,,,86,(,37,):,2615-2620.,11Hiroshi Takatani,Yoichi Nakamura,Seiji Nagashima,et al.Phase I and II trials of vinorelbine with carboplatin for patients 75 years,of age or older with previously untreated nonsmall-cell lung cancerJ.Clin Lung Cancer,2012 Jan 18.,12Resell R,,,Carcereny E,,,Gervais R,,,et a1,Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-smal1,eell lung cancer(EURTAC),:,a muhicentre,,,openlabel,。,randomised phase 3 trialJ,Lancet Once1,,,2012,,,3(3),:,239-246.,13Khozin S,,,Blumenthal GM,,,Jiang X,,,et a1,U,S,Food and Drug Administration approval summary,:,Erlotinib for the firstline treatment of metastatic nonsmall eell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 2l(L858R)substitution mutationsJ,Oncologist,,,2014,,,19(7),:,774-779,14SandierA,,,GrayR,,,PerryMC,,,et a1,Paelitaxelearboplatinalone or with bevacizumab for nonsmall-celI lung cancerf J,N Engl J Med,,,2006,,,355(24),:,2542,2550,15Ramalingam SS,,,Dahlberg SE,,,Langer CJ,,,et a1,Outcomes for elderly,,,advancedstage non small-cell lung cancer patients treated with bevaeizumab in combination with carboplatin and paclitaxel,:,analysis ofEastern Cooperative Oncology Group al 4599J,J Clin Oneel,,,2oo8,,,26(1),:,60-65,16Zhu J,,,Sharma DB,,,Gray SW,,,et a1,Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancerJ,JAMA,,,2012,,,307(15),:,15931601,17 Reek M,,,yon Pawel J,,,Zatloukal P,,,et a1,Overall survival with cisplatin gemcitabine and bevacizumab or placebo as first,1ine thempy for nonsquamous nonsmall-cell lung cancer,:,results from a randomised phase 11I trial(AVAIL)J,Ann Oncol,,,2010,,,(9),:,18041809.,18Leighl NB,,,Zatloukal P,,,Mezger J,,,et a1,Efficacy and safety of bevacizumabbased therapy in elderly patients with advaneed or,recurrent nonsquamous non-small eell lung cancer in the phase,(,B017704,),study(AVAIL)J,J Thorac Oncol,,,2010,,,5(12),:,19701976,19I Crinb L,,,Dansin E,,,Garrido P,,,et a1,Safety and eficacy of first,1ine bevacizumab,based therapy in advanced non,squamous non,smallcell lung cancer(SAiL,,,MO19390),:,a phase 4 studyJ,Lancet 0ncel,,,2010,,,1(8),:,733,740,20LynehTJ Jr,,,SpigelDR,,,Brahmer J,,,et a1,Safetyand effectiveness of bevacizumab-containing treatment for non,smal1,cell lang,cancer,:,final results of the ARIES observational cohort studyJ,J Thorac 0ncol,,,2014,,,9(9),:,13321339,1Torre LA,,,Bray F,,,Siegel RL,,,et a1,Global cancer statistics,,,2012,J,CA Cancer J Clin,,,2015,,,65(2),:,87108,2Siegel R,,,Ma J,,,Zou Z,,,et a1,Cancer statistics,,,2014J,CA Cancer J Clin,,,2014,,,64(1),:,929,3Owonikoko TK,,,Ragin CC,,,Belani CP,,,et a1,Lung cancelin elderly patients,:,an analysis of the surveillance,,,epidemiology,,,an d end results databaseJ,J Clin Oncol,,,2007,,,25(35),:,55705577,4Chen W,,,Zheng R,,,S,,,et a1,Report ofincidence and mortality,in China cancer registries,,,2OO9J,Chin J Cancer Res,,,2013,,,25,(1),:,1O,一,21,5SacherAG,,,Le LW,,,LeighlNB,,,eta1,Eldedy patientswith advanced NSCLC in phase In clinical trials,:,are the elderly eXClUded from practicechanging trials in advanced NSCLC?J,J Thorae Oncol,,,2013,,,8(3),:,366368,6Devlin JG,Langer CJ.Salvage therapy with vinorelbine in advanced non-small-cell lung cancer:a retrospective review of,the Fox Chase Cancer Center experience and a review of the literatureJ.Clin Lung Cancer,2007,8(5):319-326.,Devlin JG,et al.Clin Lung Cancer,2007,8(5):319-326.,7Rossi D,Dennetta D,Ugolini M,et al.Weekly paclitaxel in elderly patients(aged or=70 years)with advanced non-small-cell lung cancer:an alternative choice?Results of a phase II studyJ.Clin Lung Cancer,2008,9(5):280-284.,Rossi D,et al.Clin Lung Cancer,2008,9(5):280-284.,8Martoni A,Di Fabio F,Guaraldi M,et al.Prospective phase,study of single agent gemcitabine in untreated elderly patients with stage B/non-small-cell lung cancerJ.Am J Clin Oncol,2001,24(6):614-617.,Martoni A,et al.Am J Clin Oncol,2001,24(6):614-617.,9Gridelli C,Perrone F,Gallo C,et al.Chemotherapy for elderly patients with advanced non-small-cell lung cancer:the multicenter Italian lung cancer in the elderly study (MILES)phase randomized trialJ.J Natl Cancer Inst,2003,95(5):362-372.,Gridelli C,et al.J Natl Cancer Inst,2003,95(5):362-372.,10,蒋京伟,梁晓华,周鑫莉,等,.,卡铂与顺铂治疗晚期非小细胞肺癌疗效的荟萃分析,J.,中华医学杂志,,2006,,,86,(,37,):,2615-2620.,Thank You!,
展开阅读全文